Thursday, May 15, 2025 | 09:56 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Alembic Pharma targets 10-12 product filings from Karkhadi facility

Resolution of the observations made by the USFDA (for which Alembic has already responded to the regulator) is critical for Alembic's US business

Alembic Pharmaceuticals ups its US game plan, acquires Orit
Premium

Alembic Pharmaceuticals

Sohini Das Mumbai
Vadodara based drug maker Alembic Pharmaceuticals is now running exhibit batches at its Karkhadi facility (F3) to keep the plant alive and humming, while it awaits a final go-ahead from the US drug regulator.

“This way, once the plant is cleared by the US Food and Drug Administration (USFDA) we will be able to file applications for double the number of products than we would have usually. Typically, we would have been able to do four to six filings in a year from the Karkhadi plant, but as we are keeping the plant alive and humming with exhibit batches, we

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in